147results about How to "Minor side effects" patented technology

Disclosed are oral compositions comprising a stannous ion source, a polyvalent cation source and a mineral surface active agent, said compositions providing enhanced therapeutic efficacy derived from stannous fluoride and / or other stannous salt, including antimicrobial effects, control of breath malodor, control of dental plaque growth and metabolism, reduced gingivitis, decreased progression to periodontal disease, reductions in dentinal hypersensitivity and reduced coronal and root dental caries. The aforementioned benefits are provided along with significant improvements compared to conventional stannous containing compositions, including: 1) reduced levels of dental staining; 2) reduced astringency thereby improving aesthetic characteristics of the compositions; 3) reduction in dental calculus formation, and 4) enhanced stability, bioavailability and thus, efficacy of stannous. The mineral surface active agents are agents that are substantive to mineral surfaces such as teeth and have chelating activity for polyvalent cations including stannous (Sn+2), zinc (Zn+2), copper (Cu+2), aluminum (Al+2), iron (Fe+2, Fe+3), strontium (Sr+2), calcium (Ca+2), barium (Ba+2), magnesium (Mg+2), and manganese (Mn+2). Preferred mineral surface-active agents include polymers or copolymers containing phosphate, phosphonate, or carboxy groups. The compositions may also comprise a fluoride ion source and may be formulated as single phase or dual phase compositions.

Disclosed are improvements in human nutrition involving a unique combination of natural products constituting anti-inflammatory compositions which can reduce cardiovascular disease risks as well as play a positive role in other conditions and diseases for which key indicators, especially selected from the group consisting of C-reactive protein (CRP) levels, cyclooxygenase-2 (COX-2), 5-lypoxygenase (5-LOX) expression and prostaglandin E2 (PGE-2) biosynthesis or any combination of these, are indicators. Therapeutic compositions preferably comprise curcumin, bilberry extract, grape seed extract, green tea extract and apple extract, in effective amounts individually and combined to provide a therapeutically significant reduction in one or more key indicators. Another exemplified therapeutic composition comprises: omega-3 rich refined fish oil, resveratrol, blueberry extract, grape seed extract, green tea extract and gamma and / or delta tocopherol, in effective amounts individually for the above benefits.

Systems and methods according to the present invention relate to a novel peripheral nerve stimulation system for the treatment of pain, such as pain that exists after amputation.

A system and method for performing fractional resurfacing of a target area of skin using electromagnetic radiation are provided. An electromagnetic radiation is generated by an electromagnetic radiation source. The electromagnetic radiation is caused to be applied to a particular portion of a target area of skin. The electromagnetic radiation can be impeded from affecting another portion of the target area of the skin by a mask. Alternatively, the electromagnetic radiation may be applied to portions of the target area of the skin, other than the particular portion.

The present invention relates to novel methods for identifying antiviral agents which selectively interfere with viral proteins that override the interferon(IFN)-induced cellular defense mechanisms against viral infection. In particular, the present invention relates to screening assays that identify agents which selectively inhibit the interaction between viral proteins containing an interferon sensitivity determining region (ISDR) and IFN-induced PKR protein kinase. The present invention more particularly relates to screening assays that identify agents which selectively inhibit the interaction between hepatitis C virus (HCV) nonstructural 5A protein (NS5A), which contains an ISDR, and IFN-induced PKR protein kinase. The interaction between the viral ISDR and IFN-induced PKR protein kinase results in the override of IFN-induced cellular defense mechanisms to combat viral infection. Therefore the agents identified using the assays of the invention may have utility as antiviral agents.

The present invention is directed to a method and apparatus for providing electromagnetic radiation or other energy to tissue. An array of needles can be inserted at least partially into the tissue, and energy, e.g., optical energy, can be provided to the needles. The needles can include an optical waveguide configured to direct the energy to needle tips located within the tissue adjacent to one or more target regions. The energy can thus be provided directly to the target regions through the needles without being absorbed by upper portions of the tissue. Such method and apparatus can be used to treat a variety of skin conditions, including wrinkles and pigmentation defects. One or more of the needles in the array can also be hollow and configured to provide an analgesic or other substance into the tissue near the target regions.

Surgical apparatus and surgical methods are proposed for the prevention of age-related macular degeneration (AMD) and choroidal neovascularization (CNV), and other eye diseases such as glaucoma by removal of the sclera tissue to reduce its rigidity and increase the flood flow and decrease pressure in the choriocapillaris. The disclosed preferred embodiments of the system consists of a tissue ablation means and a control means of ablation patterns and a fiber delivery unit. The basic laser beam includes UV lasers and infrared lasers having wavelength ranges of (0.15-0.36) microns and (0.5-3.2) microns and diode lasers of about 0.98, 1.5 and 1.9 microns. AMD and CNV are prevented, delayed or reversed by using an ablative laser to ablate the sclera tissue in a predetermined patterns outside the limbus to increase the elasticity of the sclera tissue surrounding the eye globe The surgery apparatus also includes non-laser device of radio frequency wave, electrode device, bipolar device and plasma assisted device

A method for increasing the hardness of silica / rubber mixtures is disclosed wherein the method comprises blending with said mixture at least one silane and a hardness-increasing amount of at least one member selected from the group consisting of thixotropic fumed silica; precipitated silica; an MQ resin wherein Q is SiO4 / 2, M is R1R2R3SiO1 / 2, and R1, R2, and R3 are the same or different functional or non-functional organic groups; carbon black; a thermoplastic resin; and a thermosetting resin.

Nucleic acid sequences encoding kringle region fragments of plasminogen. Ribonucleic and deoxyribonucleic acid sequences that encode for kringle region fragments are useful for gene therapy or recombinant expression for the treatment of angiogenesis-related diseases, specifically angiogenesis-dependent cancer.

Aspirin triggered lipid mediators (ATLMs) are disclosed which are useful for the treatment of prevention of inflammation associated with various diseases, including ischemia.

The present invention provides a composition of transdermally administered alkaloids from aconitum plant for ameliorating pain and inflammation. In one aspect, an aconitum alkaloid is delivered in a sufficient amount to achieve and maintain a blood plasma aconitum alkaloid level of about 0.5 ng / mL to about 400 ng / mL. Aconitum alkaloids may be delivered by themselves, or in combination with other elements, such as additional analgesics, other drugs, or positive health promoting substances. Various formulations for the transdermal delivery of aconitum alkaloids are disclosed, and may include selected penetration enhancers.

Methods and devices for the non-thermal, electrically-induced temporary or permanent closure of blood vessels. The subject methods and devices employ pulsed electrical energy according to a defined regime to effect controlled occlusion of targeted blood vessels without heating the vessel and with minimal damage to adjacent tissue. The extent of vessel closure, i.e., temporary (vasoconstriction) or permanent (thrombosis), is controlled based on the manipulation of various parameters of the electrical stimulation regime as well as the configuration of the electrodes used to apply the regime.

An implantable or insertable medical device is provided which comprises (a) a superoxide dismutase mimic and (b) a polymeric release region. Upon administration to a patient, the polymeric release region controls the release of the superoxide dismutase mimic, which is beneficially selected from a metal-chelate superoxide dismutase mimic and a nitroxide superoxide dismutase mimic. Also provided is a method of making an implantable or insertable medical device.

The invention relates to pharmaceutical compositions and methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and / or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA. Preferably the pharmaceutical composition comprises one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, an anti-inflammatory agent, and a pharmaceutically acceptable carrier.

Certain example embodiments relate to techniques for controlling the development of a software application. The system includes an event channel for receiving at least one event that indicates an action performed by one of a plurality of existing development tools used in the development of the software application, a policy-based event engine for evaluating the at least one event and for initiating at least one action of one of the plurality of existing development tools in accordance with at least one policy, and a repository, for storing at least one artifact to define an architecture of the software application. The at least one artifact corresponds to a component of the software application and / or to a dependency between a first component and a second component of the software application.

The present invention relates generally to targeted therapy with RNA interference, more specifically, to energy susceptible nanoscale material compositions, devices for use with magnetic material compositions, and methods related thereto for targeted therapy via targeted delivery of energy susceptible nanoscale magnetic particles carrying short interfering RNA constructs.

The present invention provides novel in vivo assay systems and methods of using these assays systems to identify compounds that affect microbial cell division. The present invention further provides pharmaceutical compositions that have anti-microbial activity and methods of treating microbial infections.

The present invention provides a portable photodynamic disinfection light delivery device comprising: two opposing light sources, an energy source to supply energy to the light sources, and a housing for receiving the two light sources and the energy source; wherein (i) the housing includes two members each having a clamp portion for receiving one of the two light sources and an attachment mean connecting the clamp portions; (ii) the clamp portions during photodynamic disinfection surround a catheter disinfection site; and (iii) the two light sources together provide circumferential illumination at least one wavelength that can activate at least one photosensitizer so as to reduce microbes located at the catheter disinfection site. The present invention provides a catheter disinfection method comprising: applying circumferential illumination at a wavelength that activates a photosensitizer located at a catheter disinfection site so as to reduce microbes located at the catheter disinfection site using the portable photodynamic disinfection light device described above.

A method and apparatus are provided for treating dermatological conditions, in which a first beam of radiation is used to ablate a hole in skin tissue, and a second beam of radiation is directed into the hole and onto a region of skin tissue adjacent to and / or at the bottom of the hole. The first beam can be provided by an ablative laser such as a CO2 laser or an ER:YAG laser. The second beam can be provided by, e.g., an ablative laser operating at a lower peak power level than the first beam, a non-ablative laser, a flashlamp, a tungsten lamp, a diode or a diode array. A controlled amount of thermal damage can thereby be provided at a desired depth within the skin, using radiation sources that would be absorbed closer to the surface of the skin if an ablated hole were not present. Cooling and / or freezing of the skin prior to ablation can be provided to provide an analgesic effect and / or stabilize the tissue surrounding the ablated hole. The region of skin to be treated can optionally be pulled towards the radiation source using a vacuum to stretch and / or stabilize the skin tissue surrounding the volume to be ablated.

A sulfonyl aromatic or heteroaromatic ring hydroxamic acid compound that inter alia inhibits matrix metalloprotease activity is disclosed as are a treatment process that comprises administering a contemplated sulfonyl aromatic or heteroaromatic ring hydroxamic acid compound in a MMP enzyme-inhibiting effective amount to a host having a condition associated with pathological matrix metalloprotease activity. A contemplated compound corresponds in structure to the formulawherein W and the R groups are defined elsewhere.

The invention relates to pharmaceutical compositions and methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and / or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA. Preferably the pharmaceutical composition comprises one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, an anti-inflammatory agent, and a pharmaceutically acceptable carrier.

A therapeutic composition of lorazepam and its pharmaceutically acceptable derivatives are provided for intranasal administration of at least one predetermined volumetric unit dose in the form of a spray by means that delivers one or more therapeutically prescribed unit doses that are highly accurate as to the volume discharged and which leave no significant quantity of the composition in the delivery means.

Disclosed are oral compositions comprising a stannous ion source, a fluoride ion source, and a polymeric mineral surface active agent that binds stannous, said compositions providing adequate therapeutic efficacy with minimal side effects of tooth staining and astringency. The composition simultaneously provides reduction and control of supragingival calculus. The present oral care compositions may be formulated as single phase or dual phase compositions. The present invention also provides a method for effective delivery of stannous-containing compositions with minimal side effects of tooth staining or astringency and with effective tartar control by administering to a subject a stable dentifrice composition comprising a clinically effective amount of stannous fluoride and / or other stannous salts in combination with a fluoride ion source and a polymeric mineral surface active agent, preferably a phosphate- or phosphonate-containing polymer.

Arachidonic acid and / or compounds containing arachidonic acid as a constituent fatty acid are used to obtain compounds which prevent decline of, improve or enhance normal responses of cognitive abilities of a healthy person, and which are highly suitable for pharmaceuticals as well as food products, with minimal side effects.